#APVO
Tatsächlich haben einige Seminarleitungen kürzlich in Hannover eingefordert, dass die APVO Lehr, nach der geprüft werden muss, verändern muss.
November 15, 2026 at 10:14 AM
#$APVO raises $3M by repricing warrants, adds 13.89M new ones. Gains short-term cash but faces major future dilution. #$STIM #$EOCN #$COSM #$AMIX #$CARL #$CRVO #$CAPR #$MTNB #$CYCN #biotech

www.biopharmcatalyst.com/news/2026/bi...
Daily Updates 11/11/26
export-download.canva.com
November 11, 2026 at 9:31 PM
🚨 $APVO
On November 9, 2026, Aptevo Therapeutics Inc. issued a press release announcing that on November 7, 2026, the Company presented new preclinical data from its next-generation multispecific platform at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting.
SEC Filing: APVO
Click to view the official SEC document.
www.sec.gov
November 9, 2026 at 1:35 PM
🚨 $APVO
On November 5, 2026, Aptevo Therapeutics Inc. issued a press release announcing an important clinical development milestone for mipletamig: a substantial reduction in infusion-related reactions (IRRs) following successive refinements to its priming-dose regimen.
SEC Filing: APVO
Click to view the official SEC document.
www.sec.gov
November 5, 2026 at 1:35 PM
#APVO Aptevo Achieves Key Clinical Development Objective, Significantly Reducing Infusion-Related Reactions with Mipletamig in Fro…

https://www.stocktitan.net/news/APVO/aptevo-achieves-key-clinical-development-objective-significantly-iv41i7mx8x54.html?utm_source=stocktitan-bluesky&utm_medium=social
Aptevo Achieves Key Clinical Development Objective, Significantly Reducing Infusion-Related Reactions with Mipletamig in Frontline AML
Aptevo Therapeutics (APVO) reported fewer infusion-related reactions with mipletamig after refining the initial dosing regimen in its ongoing RAINIER study. The study evaluates mipletamig with venetoclax and azacitidine in newly diagnosed acute myeloid leukemia (AML) patients unfit for intensive chemotherapy. Aptevo described the reduction as substantial and reported favorable findings for cytokine release syndrome, a potentially serious inflammatory reaction.Previously reported findings included remission responses in TP53-mutated AML and patients advancing to stem cell transplantation. The dosing findings do not establish improved efficacy or treatment persistence. Aptevo expects to complete the current study by year-end 2026, conduct regulatory interactions and initiate Phase 2 development in 2027. Mipletamig data will be presented at the American Society of Hematology meeting on December 12–15, 2026.
www.stocktitan.net
November 5, 2026 at 1:30 PM
🚨 $APVO
Filing of Prospectus Supplement On October 30, 2026, Aptevo Therapeutics Inc. filed with the Securities and Exchange Commission (the “SEC’) a prospectus supplement (the “Prospectus Supplement” and collectively with the Prior Prospectus (as defined below), the “Prospectus”) under the Compa...
SEC Filing: APVO
Click to view the official SEC document.
www.sec.gov
November 2, 2026 at 11:03 AM
#$APVO: Per the company, 10 of 47 AML patients on Aptevo’s mipletamig combo have advanced to stem cell transplant, a potentially curative step. Early data and a small group, but a notable signal: youtu.be/y1sabVXnOl8
Aptevo’s Mipletamig Combo: 21% of AML Patients Advance to Stem Cell Transplant ($APVO)
YouTube video by Zacks Investment Awareness
youtu.be
October 30, 2026 at 9:53 PM
🚀 Zacks Small Cap Research - APVO: Mipletamig Combination Therapy Leads to 21% Stem Cell Transplantation Rate
🔎 Read the full update:
➡️https://theminingnews.com/zacks-small-cap-research-apvo-mipletamig-combination-therapy-leads-to-21-stem-cell-transplantation-rate/
#APVO #Ap
t#APVOe#AptevoTherapeuti
October 28, 2026 at 3:52 AM
#$APVO: Mipletamig Combination Therapy Leads to 21% Stem Cell Transplantation Rate buff.ly/q14Crbt
October 27, 2026 at 2:12 PM
🚨 $APVO
On October 26, 2026, Aptevo Therapeutics Inc. issued a press release announcing ten patients with newly diagnosed acute myeloid leukemia (AML) have advanced to allogeneic stem cell transplant following treatment with mipletamig in combination with venetoclax and azacitidine.
SEC Filing: APVO
Click to view the official SEC document.
www.sec.gov
October 26, 2026 at 12:13 PM
#APVO Aptevo Reports Mipletamig Combination Therapy Enabled 21% of Frontline AML Patients to Advance to Potentially Curative Stem Cell…

https://www.stocktitan.net/news/APVO/aptevo-reports-mipletamig-combination-therapy-enabled-21-of-z0rxkzoymu4o.html?utm_source=stocktitan-bluesky&utm_medium=social
Aptevo Reports Mipletamig Combination Therapy Enabled 21% of Frontline AML Patients to Advance to Potentially Curative Stem Cell Transplant
Aptevo Therapeutics (APVO) reported that 21% of evaluable frontline acute myeloid leukemia patients advanced to stem cell transplant after mipletamig combination treatment.Ten of 47 patients treated with mipletamig, venetoclax and azacitidine proceeded to donor stem cell transplantation, a potentially curative option. Nine were from the ongoing Phase 1b RAINIER trial and one from a completed dose expansion trial. These patients were initially considered unfit for intensive induction chemotherapy. Comparisons with historical venetoclax and azacitidine results are limited by differences in populations, study design and follow-up.RAINIER is a Phase 1b/2 study whose current stage evaluates mipletamig dosing. Aptevo expects to complete that work by year-end 2026 and discuss next steps with regulators in the first half of 2027.
www.stocktitan.net
October 26, 2026 at 12:05 PM
🚨 $APVO
On October 23, 2026, Aptevo Therapeutics Inc. entered into Amendment No. 6 to the Rights Agreement, dated as of November 8, 2020, between the Company and Broadridge Corporate Issuer Solutions, LLC, as rights agent . The Rights Agreement pertains to those certain contingent rights to purch...
SEC Filing: APVO
Click to view the official SEC document.
www.sec.gov
October 23, 2026 at 8:07 PM
$APVO — Other Company Update

Aptevo Therapeutics Inc. (Nasdaq: APVO) filed an 8-K announcing via press release that its multispecific platform will be presented at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, held November 4–8, 2026, in Phoenix, Arizona.

🧵 continued ↓
October 14, 2026 at 3:15 PM
🚨 $APVO
On October 14, 2026, Aptevo Therapeutics Inc. issued a press release announcing its multispecific platform will be presented at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, being held November 4–8, 2026, at the Phoenix Convention Center in Phoenix, Arizona.
SEC Filing: APVO
Click to view the official SEC document.
www.sec.gov
October 14, 2026 at 12:52 PM
🚨 $APVO
On September 24, 2026, Aptevo Therapeutics Inc. issued a press release announcing progress in its next-generation trispecific programs.
SEC Filing: APVO
Click to view the official SEC document.
www.sec.gov
September 24, 2026 at 12:59 PM
$APVO — Other Company Update

Aptevo Therapeutics announced progress in its next-generation trispecific programs, focusing on optimizing candidates for scalable manufacturing ahead of future human testing. The lead candidate, APVO451, is expected to enter IND-enabling studies in 1H...

🧵 continued ↓
September 24, 2026 at 7:17 PM
🚨 $APVO
On September 22, 2026, Aptevo Therapeutics Inc. held its Special Meeting of Stockholders , at which a quorum was present.
SEC Filing: APVO
Click to view the official SEC document.
www.sec.gov
September 23, 2026 at 8:45 PM
Just spoke to the police ... They suggested an avo

Hugz & xXx
September 14, 2026 at 4:39 AM